Donepezil May Be Effective For Down’s Syndrome
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Donepezil May Be Effective For Down’s Syndrome

LONDON, ENGLAND -- March 26, 1999 -- It is usually assumed that the disabilities associated with Down's syndrome are untreatable. In a research letter in this week's issue of The Lancet, Dr. Priya Kishnani and colleagues, from Duke University Medical School, Durham, N.C., report an improvement in communication, language ability and mood in four people with Down's syndrome treated with donepezil, a drug usually used to treat dementia.

Down's syndrome is caused by a disorder of chromosomes that cannot be corrected. The effects of this disorder, especially in older people with Down's syndrome, are similar to those seen in people with dementia due to Alzheimer's disease: poor communication, short attention span and changeable mood. Over the past few years, a drug that alters the way brain cells communicate with each other, donepezil, has been shown to help people with Alzheimer's disease.

Dr. Kishnani and colleagues tried donepezil on four people, aged 24 to 67 years, with Down's syndrome. Beneficial effects were seen within the first three months of treatment. The researchers report that improvements in communication, expressive language, attention and mood stability were noted in all four patients.

The researchers do not claim their small study should lead to widespread use of donepezil, but conclude that, a larger randomised placebo-controlled trial of cholinergic therapy in Down's syndrome is warranted.

Related Links: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities